Healthcare Industry News: Acute Coronary Syndrome
News Release - December 21, 2006
Momenta Pharmaceuticals Announces Executive PromotionCAMBRIDGE, Mass., Dec. 21 (HSMN NewsFeed) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA ), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that John E. Bishop, Ph.D., has been promoted to Senior Vice President, Pharmaceutical Sciences. Dr. Bishop previously served as Vice President, Pharmaceutical Sciences and Manufacturing for Momenta.
"John has been a valuable member of our executive team through his leadership of our manufacturing program for key products in our pipeline," said Craig Wheeler, President and Chief Executive Officer of Momenta. "In particular, he has been instrumental in advancing the analytic and process development work for M-Enoxaparin. This promotion is recognition of his hard work and the significant contribution he has made to Momenta's progress. John's leadership will be vital as we continue to advance our novel drug candidate, M118, as well as our broader complex generics strategy."
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed characterization and engineering of complex drugs. Momenta is applying its technology to create technology-enabled generic versions of sugar-based and other complex drug products, develop improved versions of existing drugs, and discover novel drugs and new biological processes. The Company's most advanced product candidate is M-Enoxaparin, a technology- enabled generic version of Lovenox®. Momenta's first novel drug candidate is M118, a rationally engineered anticoagulant specifically designed for Acute Coronary Syndromes. The Company is developing other novel drug candidates through its discovery effort focused on understanding sugar-based biological processes. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Source: Momenta Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.